Geneva, June 20 -- International Clinical Trials Registry received information related to the study (ISRCTN16084957) titled 'VITAL01: A study of a new vaccine against Lassa fever in adults aged 18-55 years' on June 11.
Study Type: Interventional
Study Design:
Randomized controlled trial (Prevention, Treatment, Safety)
Primary Sponsor: University of Oxford
Condition:
Lassa virus
Infections and Infestations
Intervention:
The study's main purpose is to assess the vaccine's safety and the immune response that develops in vaccinated people. The study will recruit up to 31 healthy people aged 18 to 55 years old. Participants will be screened for eligibility using an online questionnaire and a telephone call, followed by an in-person me...